Eric J. Small
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (43)
Year:
2026
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
Year:
2025
Hierarchical clustering analyses of benign, localized, and mCRPC tumors representing the expression of neuroendocrine marker genes (NE), androgen-related genes (AR), and genes related to squamous (SQUAM) differentiation
Year:
2025
Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.
Year:
2025
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
Year:
2025
Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.
Year:
2025
Supplemental Movies 2a-2c: 22Rv1-NuclightGreen and SHP-77-NuclightRed mixed population co-cultures. Time-lapse movies of 22Rv1 cells (labeled with NuclightGreen) and SHP-77 cells (labeled with NuclightRed) co-cultured with T cells. Both the 22Rv1 and SHP-77 cells were plated at equal densities and treated with either NT control BiTE®, AMG 757, or the PSMA-targeting HLE BiTE, AMG 160. T cells were added to each well at an E:T ratio of 10:1. Images were captured every 4 hours at 4x magnification for 5 days. a. 22Rv1, SHP-77, and T cells co-cultured with NT control BiTE®. b. 22Rv1, SHP-77, and T cells co-cultured with AMG 757. c. 22Rv1, SHP-77, and T cells co-cultured with AMG 160.
Year:
2025
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
Year:
2025
Supplemental Movies 1a-1d: 22Rv1-LacZ and 22Rv1-DLL3 cells co-cultures. Time-lapse movies of 22Rv1-LacZ and 22Rv1-DLL3 cells (labeled with NuclightRed) co-cultured with T cells and either NT control BiTE® or AMG 757. T cells were plated at an E:T ratio of 5:1. Images were captured every 6 hours at 10x magnification. a. 22Rv1-LacZ cells and T cells treated with NT control BiTE®. b. 22Rv1-DLL3 cells and T cells treated with NT control BiTE®. c. 22Rv1-LacZ cells and T cells treated with AMG 757. d. 22Rv1-DLL3 cells and T cells treated with AMG 757.
Year:
2025
Purpose: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, especially using large cohorts. Thus, we sought to identify the intrinsic molecular subtypes of mCRPC and assess molecular and clinical correlates in the largest combined cohort of mCRPC samples with gene expression data available to date. Experimental Design: We combined and batch-effect corrected gene expression data from four mCRPC cohorts from the Fred Hutchinson Cancer Research Center ( N = 157), a small-cell neuroendocrine (NE) prostate cancer (SCNC)–enriched cohort from Weill Cornell Medicine ( N = 49), and cohorts from the Stand Up 2 Cancer/Prostate Cancer Foundation East Coast Dream Team ( N = 266) and the West Coast Dream Team ( N = 162). Results: Hierarchical clustering of RNA-sequencing data from these 634 mCRPC samples identified two distinct adenocarcinoma subtypes, one of which (adeno-immune) was characterized by higher gene expression of immune pathways, higher CIBERSORTx immune scores, diminished ASI benefit, and non–lymph node metastasis tropism compared with an adeno-classic subtype. We also identified two distinct subtypes with enrichment for an NE phenotype, including an NE-liver subgroup characterized by liver metastasis tropism, PTEN loss, and APC and SPOP mutations compared with an NE-classic subgroup. Conclusions: Our results emphasize the heterogeneity of mCRPC beyond currently accepted molecular phenotypes, and suggest that future studies should consider incorporating transcriptome-wide profiling to better understand how these differences impact treatment responses and outcomes.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (33)
Meng Zhang
Assistant Professor of Urology
Emory University
David A. Quigley
Assistant Professor
University of California, San Francisco
Joshua Lang
Professor
University of Wisconsin-Madison
Arul M Chinnaiyan
University of Michigan
Michelle R. Arkin
Professor and Department Chair
University of California
Jiaoti Huang
Professor and Chairman
Duke Medicine
Alan Ashworth
University of California, San Francisco
Alexander W. Wyatt
Assistant Professor
The University of British Columbia
Matthew Rettig
Professor
University of California, Los Angeles
Shuang G. Zhao
University of Wisconsin-Madison
Li Zhang
Professor
UCSF
Emily Chan
Stanford University
Kim Chi
Chief Medical Officer
BC Cancer
Lixing Yang
University of Chicago
Michelle Badura
Lecturer
Santa Clara University
Raunak Shrestha
Assistant Professor
Uniformed Services University of the Health Sciences
Fred Saad
Université de Montréal
Tomasz Michal Beer
Oregon Health & Science University
Emily Egusa
University of California, San Francisco
Anil Parsram Bidkar
Assistant Professional Researcher
University of California, San Francisco
Lawrence Fong
Fred Hutch Cancer Center
Owen Witte
University Professor
University of California, Los Angeles
Brandon Chen
University of California, San Francisco
Arian Lundberg
Assistant Professor at KTH Royal Institute of Technology
KTH Royal Institute of Technology
Jonathan Chou
Assistant Professor
University of California, San Francisco
sinan wang
Assistant Professor
University of California, San Francisco
Felix Y. Feng
University of California
Christopher Evans
Professor
University of California, Davis
Robert R. Flavell
University of California
Minkyu Kim
University of California
Mathieu Lupien
Senior Scientist
University Health Network
Rahul Aggarwal
University of California
Terence Friedlander
University of California, San Francisco
Make your next move.
Prepare your application
Review drafts before you send them.